Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics

PCRX POWR Grades

• Growth is the dimension where PCRX ranks best; there it ranks ahead of 80.44% of US stocks.
• The strongest trend for PCRX is in Quality, which has been heading up over the past 179 days.
• PCRX ranks lowest in Sentiment; there it ranks in the 6th percentile.

PCRX Stock Summary

• With a price/earnings ratio of 107.49, PACIRA BIOSCIENCES INC P/E ratio is greater than that of about 95.79% of stocks in our set with positive earnings.
• With a year-over-year growth in debt of 48.16%, PACIRA BIOSCIENCES INC's debt growth rate surpasses 79.66% of about US stocks.
• In terms of twelve month growth in earnings before interest and taxes, PACIRA BIOSCIENCES INC is reporting a growth rate of -37.76%; that's higher than 27.47% of US stocks.
• Stocks that are quantitatively similar to PCRX, based on their financial statements, market capitalization, and price volatility, are ATY, ROVR, STAA, OSS, and PAYC.
• PCRX's SEC filings can be seen here. And to visit PACIRA BIOSCIENCES INC's official web site, go to www.pacira.com.

PCRX Valuation Summary

• PCRX's price/earnings ratio is 109.2; this is 370.69% higher than that of the median Healthcare stock.
• PCRX's EV/EBIT ratio has moved up 51.7 over the prior 144 months.

Below are key valuation metrics over time for PCRX.

PCRX Growth Metrics

The 3 year cash and equivalents growth rate now stands at 5.45%.
• Its 5 year net income to common stockholders growth rate is now at 99.77%.
• Its year over year net income to common stockholders growth rate is now at -73.98%.

Over the past 15 months, PCRX's revenue has gone up $150,987,000.

The table below shows PCRX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	654.062	126.452	20.881
2022-06-30	614.318	144.085	39.234
2022-03-31	580.497	144.413	38.439
2021-12-31	541.533	125.717	41.98
2021-09-30	513.313	149.169	61.625
2021-06-30	503.075	128.663	174.084

PCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• PCRX has a Quality Grade of C, ranking ahead of 72.8% of graded US stocks.
• PCRX's asset turnover comes in at 0.394 -- ranking 116th of 681 Pharmaceutical Products stocks.
• BCDA, NVAX, and RDHL are the stocks whose asset turnover ratios are most correlated with PCRX.

The table below shows PCRX's key quality metrics over time.